Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -68.91 is 81% above its 5-year average of -367.67, near the high end of its 5-year range (-606.00–-68.91).
76.95% above its 12-month average of -299.00.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -12.31.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 29 comparable quarters.
EARNINGS PER SHARE (EPS)
-68.91
EARNINGS PER SHARE (EPS) AVG TTM
-299.00
EARNINGS PER SHARE (EPS) AVG 3Y
-268.50
EARNINGS PER SHARE (EPS) AVG 5Y
-367.67
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+76.95%
CURRENT VS 3Y AVG
+74.34%
CURRENT VS 5Y AVG
+81.26%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Quince Therapeutics, Inc.
Market Cap
$7.60M
Earnings Per Share (EPS)
-68.91
TTM Avg
-299.00
3Y Avg
-268.50
5Y Avg
-367.67
Market Cap
$7.87M
Earnings Per Share (EPS)
-6.39
TTM Avg
-9.59
3Y Avg
-7.41
5Y Avg
-7.93
Market Cap
$7.96M
Earnings Per Share (EPS)
-1.08
TTM Avg
-2.14
3Y Avg
-342.00
5Y Avg
-242.25
Market Cap
$7.96M
Earnings Per Share (EPS)
-104.00
TTM Avg
-164.88
3Y Avg
-121.81
5Y Avg
-116.67
Market Cap
$7.96M
Earnings Per Share (EPS)
-23.59
TTM Avg
-251.09
3Y Avg
-121778.80
5Y Avg
-249058.36
Market Cap
$7.31M
Earnings Per Share (EPS)
-10.16
TTM Avg
-8.56
3Y Avg
-32.56
5Y Avg
-37.85
Market Cap
$7.31M
Earnings Per Share (EPS)
-3.48
TTM Avg
-5.74
3Y Avg
-24.14
5Y Avg
-2936.24
Market Cap
$7.27M
Earnings Per Share (EPS)
-10.10
TTM Avg
-11.80
3Y Avg
-53.95
5Y Avg
-54.65
Market Cap
$8.23M
Earnings Per Share (EPS)
N/A
TTM Avg
-6.41
3Y Avg
-27.87
5Y Avg
-55.81
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | $7.60M | -68.91 | -299.00 | -268.50 | -367.67 |
| ENDRA Life Sciences Inc. (NDRA)vs › | $7.87M | -6.39 | -9.59 | -7.41 | -7.93 |
| Aprea Therapeutics, Inc. (APRE)vs › | $7.96M | -1.08 | -2.14 | -342.00 | -242.25 |
| GT Biopharma, Inc. (GTBP)vs › | $7.96M | -104.00 | -164.88 | -121.81 | -116.67 |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.96M | -23.59 | -251.09 | -121778.80 | -249058.36 |
| Skye Bioscience, Inc. (SKYE)vs › | $7.31M | -10.16 | -8.56 | -32.56 | -37.85 |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | -3.48 | -5.74 | -24.14 | -2936.24 |
| Longeveron Inc. (LGVN)vs › | $7.27M | -10.10 | -11.80 | -53.95 | -54.65 |
| HeartSciences Inc. (HSCS)vs › | $8.23M | N/A | -6.41 | -27.87 | -55.81 |
| Mangoceuticals, Inc. (MGRX)vs › | $7.08M | -1.16 | -3.29 | -3.69 | -2.95 |
Trailing EPS (TTM)
$-68.91
Forward EPS (Est.)
$-9.78
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -336.00 |
| 2024-12-31 | -262.00 |
| 2023-12-31 | -168.00 |
| 2022-12-31 | -308.00 |
| 2021-12-31 | -606.00 |
| 2020-12-31 | -526.00 |
| 2019-12-31 | -386.00 |
| 2018-12-31 | -116.00 |
| 2017-12-31 | -114.00 |
